Friday, October 07, 2011 8:58:06 AM
Solutia to Acquire Southwall Technologies Inc.
Creates powerhouse of world-class innovation, technology and commercial films expertise
Press Release Source: Solutia Inc.; Southwall Technologies Inc. On Friday October 7, 2011, 8:30 am
ST. LOUIS and PALO ALTO, Calif., Oct. 7, 2011 /PRNewswire/ -- Solutia Inc. (NYSE:SOA - News), a market-leading performance materials and specialty chemicals company, and Southwall Technologies Inc. (NASDAQ:SWTX - News), a leading innovator of energy-saving films and glass products for automotive and architectural markets, today announced that they have signed a definitive agreement providing for Solutia to acquire Southwall for $13.60 per share of Southwall common stock in cash. The transaction, which has been approved by the boards of directors of both companies, has an aggregate equity purchase price of approximately $113 million. The acquisition will be funded by Solutia from existing cash on hand.
Creates powerhouse of world-class innovation, technology and commercial films expertise
Press Release Source: Solutia Inc.; Southwall Technologies Inc. On Friday October 7, 2011, 8:30 am
ST. LOUIS and PALO ALTO, Calif., Oct. 7, 2011 /PRNewswire/ -- Solutia Inc. (NYSE:SOA - News), a market-leading performance materials and specialty chemicals company, and Southwall Technologies Inc. (NASDAQ:SWTX - News), a leading innovator of energy-saving films and glass products for automotive and architectural markets, today announced that they have signed a definitive agreement providing for Solutia to acquire Southwall for $13.60 per share of Southwall common stock in cash. The transaction, which has been approved by the boards of directors of both companies, has an aggregate equity purchase price of approximately $113 million. The acquisition will be funded by Solutia from existing cash on hand.
Recent SWTX News
- SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology • GlobeNewswire Inc. • 10/21/2025 06:00:13 AM
- European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors • GlobeNewswire Inc. • 08/18/2025 01:10:52 PM
- European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN • GlobeNewswire Inc. • 07/18/2025 03:30:23 PM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 07/11/2025 10:00:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2025 08:26:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2025 08:23:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2025 08:22:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2025 08:21:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2025 08:19:20 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 07/01/2025 08:11:31 PM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 07/01/2025 08:03:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/01/2025 12:38:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/26/2025 08:45:17 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/16/2025 10:16:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/16/2025 10:15:03 AM
- SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN • GlobeNewswire Inc. • 05/23/2025 12:00:00 PM

